Macrogenics (MGNX) Tax Provisions (2024 - 2025)
Macrogenics (MGNX) reported Tax Provisions of -$805000.0 for Q4 2025, down 185.28% year-over-year from $944000.0 in Q4 2024, and down 866.67% quarter-over-quarter from $105000.0 in Q2 2025.
Macrogenics (MGNX) Tax Provisions (2024 - 2025) Analysis & Trends
Macrogenics (MGNX) has 2 years of Tax Provisions data on file, last reported at -$805000.0 in Q4 2025.
- Tax Provisions for Q4 2025 came in at -$805000.0, down 185.28% year-over-year; the trailing twelve-month figure through Dec 2025 was $244000.0 (changed N/A YoY), and the FY2025 annual result was -$700000.0, down 174.15% from the prior year.
- Tax Provisions eased to -$805000.0 in Q4 2025 per MGNX's latest filing, from $105000.0 in the prior quarter.
- Over five years, Tax Provisions peaked at $944000.0 in Q4 2024 and troughed at -$805000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -11.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 216,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -859,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 221.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Macrogenics | 260.14 Mn | 193.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -805,000.00 |
| Jun 30, 2025 | 105,000.00 |
| Dec 31, 2024 | 944,000.00 |